2021 | United States military veterans | Randomized placebo-controlled trial
Bonn-Miller MO et al. PLOS ONE. 2021;16:e0246990.
Methods:In the first stage, 80 veterans were assigned to three weeks of THC-dominant, CBD-dominant, combined THC/CBD, or placebo cannabis. The primary endpoint compared changes in PTSD severity during this stage.
Findings: Symptoms improved in all groups, including placebo. None of the active cannabis preparations significantly outperformed placebo on the primary PTSD comparison.
Limitations: This was a brief preliminary trial with small treatment groups and a strong placebo response. It cannot establish longer-term effectiveness, effects of other formulations, or benefit for every PTSD symptom.